Gain-of-function variants and overexpression of RUNX2 in patients with nonsyndromic midline craniosynostosis

Araceli Cuellar, Krithi Bala, Lorena Di Pietro, Marta Barba, Garima Yagnik, Jia Lie Liu, Christina Stevens, David J. Hur, Roxann G. Ingersoll, Cristina M. Justice, Hicham Drissi, Jinoh Kim, Wanda Lattanzi, Simeon A. Boyadjiev

Research output: Contribution to journalArticle

Abstract

Craniosynostosis (CS), the premature fusion of one or more cranial sutures, is a relatively common congenital anomaly, occurring in 3–5 per 10,000 live births. Nonsyndromic CS (NCS) accounts for up to 80% of all CS cases, yet the genetic factors contributing to the disorder remain largely unknown. The RUNX2 gene, encoding a transcription factor critical for bone and skull development, is a well known CS candidate gene, as copy number variations of this gene locus have been found in patients with syndromic craniosynostosis. In the present study, we aimed to characterize RUNX2 to better understand its role in the genetic etiology and in the molecular mechanisms underlying midline suture ossification in NCS. We report four nonsynonymous variants, one intronic variant and one 18 bp in-frame deletion in RUNX2 not found in our study control population. Significant difference in allele frequency (AF) for the deletion variant RUNX2 p.Ala84-Ala89del (ClinVar 257,095; dbSNP rs11498192) was observed in our sagittal NCS cohort when compared to the general population (P = 1.28 × 10−6), suggesting a possible role in the etiology of NCS. Dual-luciferase assays showed that three of four tested RUNX2 variants conferred a gain-of-function effect on RUNX2, further suggesting their putative pathogenicity in the tested NCS cases. Downregulation of RUNX2 expression was observed in prematurely ossified midline sutures. Metopic sites showed significant downregulation of promoter 1-specific isoforms compared to sagittal sites. Suture-derived mesenchymal stromal cells showed an increased expression of RUNX2 over matched unfused suture derived cells. This demonstrates that RUNX2, and particularly the distal promoter 1-isoform group, are overexpressed in the osteogenic precursors within the pathological suture sites.

Original languageEnglish (US)
Article number115395
JournalBone
Volume137
DOIs
StatePublished - Aug 2020

Keywords

  • Birth defect
  • Craniofacial
  • Mesenchymal stromal cells
  • Nonsyndromic craniosynostosis
  • Osteogenesis
  • RUNX2

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Physiology
  • Histology

Fingerprint Dive into the research topics of 'Gain-of-function variants and overexpression of RUNX2 in patients with nonsyndromic midline craniosynostosis'. Together they form a unique fingerprint.

  • Cite this

    Cuellar, A., Bala, K., Di Pietro, L., Barba, M., Yagnik, G., Liu, J. L., Stevens, C., Hur, D. J., Ingersoll, R. G., Justice, C. M., Drissi, H., Kim, J., Lattanzi, W., & Boyadjiev, S. A. (2020). Gain-of-function variants and overexpression of RUNX2 in patients with nonsyndromic midline craniosynostosis. Bone, 137, [115395]. https://doi.org/10.1016/j.bone.2020.115395